Definitive Healthcare (NASDAQ:DH) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Definitive Healthcare (NASDAQ:DH) issued its earnings results on Thursday. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01, FiscalAI reports. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.14%. The company had revenue of $60.05 million for the quarter, compared to analysts’ expectations of $59.51 million. Definitive Healthcare updated its FY 2025 guidance to 0.230-0.240 EPS and its Q4 2025 guidance to 0.050-0.060 EPS.

Definitive Healthcare Trading Up 10.6%

NASDAQ:DH traded up $0.28 during mid-day trading on Friday, reaching $2.93. 502,544 shares of the company’s stock traded hands, compared to its average volume of 251,544. Definitive Healthcare has a 12-month low of $2.15 and a 12-month high of $5.68. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.65 and a quick ratio of 1.65. The company has a 50 day moving average price of $3.46 and a 200-day moving average price of $3.57. The firm has a market capitalization of $419.41 million, a price-to-earnings ratio of -1.75 and a beta of 1.61.

Analyst Ratings Changes

Several research analysts have recently commented on DH shares. William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a report on Thursday. Stifel Nicolaus raised their price target on Definitive Healthcare from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definitive Healthcare in a research report on Wednesday, October 8th. Finally, Robert W. Baird set a $4.00 price objective on Definitive Healthcare in a research note on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $4.28.

Hedge Funds Weigh In On Definitive Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in DH. AQR Capital Management LLC boosted its holdings in Definitive Healthcare by 56.7% in the first quarter. AQR Capital Management LLC now owns 590,149 shares of the company’s stock valued at $1,706,000 after acquiring an additional 213,562 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock worth $25,191,000 after purchasing an additional 7,404,363 shares during the period. Jane Street Group LLC boosted its stake in shares of Definitive Healthcare by 166.0% during the 1st quarter. Jane Street Group LLC now owns 105,114 shares of the company’s stock valued at $304,000 after purchasing an additional 65,597 shares in the last quarter. Creative Planning boosted its stake in shares of Definitive Healthcare by 41.7% during the 2nd quarter. Creative Planning now owns 28,628 shares of the company’s stock valued at $112,000 after purchasing an additional 8,428 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Definitive Healthcare during the second quarter valued at about $4,247,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.